APPLICATIONS
ACUTE MYOCARDIAL INFARCTION RULE OUT MULTIPLEXED TROPONIN I AND COPEPTIN MEASURMENT
One of the leading causes of emergency department visitation is symptoms indicating acute coronary syndrome (ACS). In 2015 the US National Hospital Ambulatory Medical Care Survey (NHAMCS) indicated the number of suspected ACS cases as 7.3 million and of that only 1.05 million (14.4%) resulted in the diagnosis of ACS with similar statistics worldwide. The statistics indicate the necessity of effective and rapid patients triage to decrease emergency departments overcrowding, associated costs and increase urgency in starting treatment.
One of the leading causes of emergency department visitation is symptoms indicating acute coronary syndrome (ACS). In 2015 the US National Hospital Ambulatory Medical Care Survey (NHAMCS) indicated the number of suspected ACS cases as 7.3 million and of that only 1.05 million (14.4%) resulted in the diagnosis of ACS with similar statistics worldwide. The statistics indicate the necessity of effective and rapid patients triage to decrease emergency departments overcrowding, associated costs and increase urgency in starting treatment.
Fourth Universal Definition of Myocardial Infarction (MI) provides the following clinical criteria for myocardial infarction: "The clinical definition of MI denotes the presence of acute myocardial injury detected by abnormal cardiac biomarkers in the setting of evidence of acute myocardial ischemia."
Cardiac Troponins I and T testing became the gold standard for the diagnosis of acute myocardial infarction in patients presenting with ACS and non-ACS MI. Contemporary cardiac troponins diagnostic equipment provides different levels of sensitivity and due to delayed troponins release kinetics during acute myocardial infarction requires central laboratory serial testing which takes from 1 to 6 hours and from 2 to 3 measurements. Utilization of the newest high sensitivity equipment takes up to 1 hour for detection. Point-of-care testing devices are unable to reach the high-sensitivity level. This leads to overcrowding of emergency departments, lack of beds in cardiac observation units and delays in life-saving treatments.
Leading medical institutions and experts together with regulators conducted CHOPIN study confirming that simultaneous detection of Troponin and Copeptin allows safe rule out of AMI with a Negative Predictive Value >99% in patients presenting with suspected ACS. Moreover, cost analysis of combined copeptin/cardiac troponin testing versus serial cardiac troponin testing in patients with suspected ACS showed the potential to save costs and staff time in acute care and for the entire hospital stay.
Our proprietary technology allows multiplexed detection of Troponin I and Copeptin with medically relevant sensitivity and precision which is currently set at 10 pmol/L for Copepin and Troponin I concentration at 99th percentile of that of the healthy population.
The use of the dual-marker strategy is recommended for the rapid ruleout of AMI by current European Society of Cardiology guidelines.
The use of the dual-marker strategy is recommended for the rapid ruleout of AMI by current European Society of Cardiology guidelines.